Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
Curigliano G, Curigliano H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, Wilgenhof S, Santoro A, Sabatos-Peyton CA, Longmire TA, Xyrafas A, Sun H, Gutzwiller S, Manenti L, Naing A.
Curigliano G, et al. Among authors: manenti l.
Clin Cancer Res. 2024 Sep 3;30(17):3957. doi: 10.1158/1078-0432.CCR-24-2131.
Clin Cancer Res. 2024.
PMID: 39224022
No abstract available.